Product Description
Bremelanotide injection is used to treat women with hypoactive sexual desire disorder (HSDD; a low sexual desire that causes distress or interpersonal difficulty) who have not experienced menopause (change of life; the end of monthly menstrual periods); who have not had problems with low sexual desire in the past; and whose low sexual desire is not due to a medical or mental health problem, a relationship problem, or medication or other drug use. Bremelanotide injection should not be used for the treatment of HSDD in women who have gone through menopause, in men, or to improve sexual performance. Bremelanotide injection is in a class of medications called melanocortin receptor agonists. It works by activating certain natural substances in the brain that control mood and thinking. (Sourced from: https://medlineplus.gov/druginfo/meds/a619054.html)
Mechanisms of Action: MCR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Palatin Technologies
Company Location: CRANBURY NJ 08512
Company CEO: Carl Spana
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Hypokinesia
Phase 2: Diabetic Nephropathy|Kidney Diseases|Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BMT-801 | P2 |
Recruiting |
Obesity |
2024-12-31 |
|
| BREAKOUT | P2 |
Completed |
Diabetic Nephropathy|Kidney Diseases |
2024-04-26 |
|
| KD-BMT-301 | P3 |
Completed |
Hypokinesia |
2023-05-16 |